Novartis

De Silva named president and CEO of Endo Health Solutions

Wednesday, February 27, 2013 11:25 AM

Endo Health Solutions, a Malvern, Penn.-based diversified healthcare company, has named Rajiv De Silva as president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds David Holveck, who is retiring.

More... »

Novartis, Dr. Vasella cancel non-compete agreement

Wednesday, February 20, 2013 09:29 AM

The Novartis board of directors and Dr. Daniel Vasella, chairman of the company’s board, have agreed to cancel Vasella’s non-compete agreement with Novartis and all related conditional compensation. The agreement was to take effect after Vasella steps down as chairman of the board on February 22, 2013.

More... »

AcelRx appoints Adrian Adams to board

Tuesday, February 12, 2013 08:00 AM

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on acute and breakthrough pain, has appointed Adrian Adams, CEO and president of Auxilium Pharmaceuticals, to its board of directors as chairman of the board.  

More... »

The CenterWatch Monthly, February 2013

Friday, February 1, 2013 10:48 AM

Sized out of big deals, mid-tier CROs still thriving

More... »

FDA approves Gleevec for children with acute lymphoblastic leukemia

Monday, January 28, 2013 11:22 AM

The FDA has approved a new use for Novartis’ Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

More... »

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Novartis to build $500M biotech facility in Singapore

Wednesday, October 31, 2012 01:38 PM

Novartis has decided to construct a new state-of-the-art biotechnology production site in Singapore with an investment valued at over $500 million.

More... »

Novartis receives E.C. approval for once-daily Seebri Breezhaler for COPD

Monday, October 1, 2012 12:11 PM

The European Commission has approved Novartis’ Seebri Breezhaler (glycopyrronium bromide) 44µg delivered dose, as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

More... »

Emory to receive $6 million for AIDS vaccine research

Friday, September 21, 2012 11:04 AM

A team of researchers at Emory University has received a three-year grant of $6 million from the Bill & Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD), an international network of scientists and experts dedicated to developing an effective vaccine for HIV/AIDS.

More... »

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »